8-K: Journey Medical Reports Strong Q3 Growth, Emrosi Drives Revenue

Journey Medical Corporation announced robust third-quarter 2025 financial results, driven by a 21% year-over-year revenue increase and significant growth in its key dermatology product, Emrosi.

Summary

• Third quarter 2025 net revenues increased 21% year-over-year to $17.6 million, up from $14.6 million in Q3 2024.
• Emrosi generated $4.9 million in net sales in Q3 2025, with total prescriptions increasing 146% over Q2 2025.
• Gross margin improved sequentially in 2025, reaching 67.4% in Q3, driven by higher-margin products like Emrosi and Qbrexza.
• Net loss slightly improved to $2.3 million in Q3 2025 from $2.4 million in Q3 2024.
• Adjusted EBITDA significantly improved to a positive $1.7 million in Q3 2025, compared to $0.3 million in Q3 2024.
• Cash and cash equivalents stood at $24.9 million as of September 30, 2025, an increase from $20.3 million at December 31, 2024.
• Emrosi demonstrated superior efficacy in a pooled Phase 3 analysis, confirming clinical superiority over placebo and doxycycline for inflammatory lesions of rosacea.
• Expanded payer access for Emrosi to over 100 million commercial lives in the U.S. by July 2025, up from 54 million in May 2025.

Sentiment

Score: 7

Explanation: The company demonstrated strong commercial momentum with significant revenue growth driven by its key product Emrosi, improved Adjusted EBITDA, and expanded market access. While still reporting a net loss and facing industry risks, the positive trajectory and clinical validation of Emrosi are encouraging.

Positives

• Net revenues increased 21% year-over-year to $17.6 million in Q3 2025.
• Emrosi net revenues reached $4.9 million in Q3 2025, demonstrating strong market adoption.
• Emrosi total prescriptions surged 146% over Q2 2025.
• Gross margin showed sequential improvement throughout 2025, reaching 67.4% in Q3, driven by higher-margin products.
• Adjusted EBITDA improved significantly to a positive $1.7 million in Q3 2025 from $0.3 million in Q3 2024.
• Net loss narrowed slightly to $2.3 million in Q3 2025 from $2.4 million in Q3 2024.
• Cash and cash equivalents increased to $24.9 million by September 30, 2025, from $20.3 million at year-end 2024.
• Emrosi's clinical differentiation was validated by a pooled Phase 3 efficacy analysis, confirming statistically significant superiority over Oracea and placebo.
• Expanded payer access for Emrosi to over 100 million commercial lives in the U.S. by July 2025, a substantial increase from 54 million in May 2025.

Negatives

• Gross margin of 67.4% in Q3 2025 was lower than 69.4% in Q3 2024, though the prior year was impacted by one-time adjustments.
• Selling, general and administrative (SG&A) expenses increased 6% to $12.1 million, primarily due to Emrosi's launch and commercialization activities.
• The company reported a net loss of $2.3 million for the quarter.
• EBITDA remained negative at $(0.5) million, despite an improvement from the prior year.

Risks

• Products and product candidates are subject to time and cost-intensive regulation and clinical testing, and may never be successfully developed or commercialized.
• A substantial portion of sales derive from products that may become subject to third-party generic competition, new competitor products, or an increase in market share of existing competitor products.
• Operating in a heavily regulated industry, with unpredictable impacts from future legislation or administrative/executive action.
• Revenue is mainly dependent upon sales of dermatology products, and any setback could impair operating results.
• Competition could limit commercial opportunity and profitability, including from manufacturers of generic versions of products.
• Risk that products do not achieve broad market acceptance, including by government and third-party payors.
• Reliance on third parties for several aspects of operations.
• Dependence on the ability to identify, develop, and acquire or in-license products and integrate them into operations.
• Success of the business, including ability to finance and generate additional revenue, depends on the successful commercialization of Emrosi and any future product candidates.
• Clinical drug development is very expensive, time-consuming, and uncertain, and clinical trials may fail to adequately demonstrate safety and efficacy.
• Competitors could develop and commercialize products similar or identical to ours.
• Risks related to the protection of intellectual property and potential inability to maintain sufficient patent protection.
• Business and operations would suffer in the event of computer system failures, cyber-attacks, or cybersecurity deficiencies.
• Substantial doubt about the ability to continue as a going concern.
• Effects of major public health issues, epidemics, or pandemics on product revenues and future clinical trials.
• Potential need to raise additional capital.
• Fortress Biotech, Inc. controls a voting majority of common stock, which could be detrimental to other shareholders.

Future Outlook

Management anticipates continued growth of Emrosi and leveraging its established dermatology commercial infrastructure to generate significant operating leverage. The company believes Emrosi is well-positioned to become the preferred treatment for inflammatory lesions of rosacea as it gains recognition among dermatologists and patients.

Management Comments

• "Our third quarter 2025 results reflect continued strong execution and accelerating commercial momentum, with revenue increasing 21% year-over-year to $17.6 million."
• "Emrosi continues to drive growth, generating $4.9 million in net sales in the third quarter alone, supported by robust market adoption and payer access that continues to expand."
• "We anticipate the growth of Emrosi and our established dermatology commercial infrastructure to generate significant operating leverage going forward."
• "Emrosis clinical differentiation was further validated this quarter through a pooled Phase 3 efficacy analysis presented at the Fall Clinical Dermatology Conference, which confirmed statistically significant clinical superiority over both Oracea and placebo."
• "As Emrosi gains recognition among both dermatologists and patients, we believe it is well-positioned to become the preferred treatment for inflammatory lesions of rosacea."

Industry Context

Journey Medical operates in the competitive dermatology pharmaceutical market, focusing on FDA-approved prescription products. The strong performance of Emrosi, particularly its rapid prescription growth and expanded payer access, indicates successful penetration in the rosacea treatment segment. The validation of Emrosi's clinical superiority through Phase 3 data positions it favorably against existing treatments like Oracea, suggesting a potential shift in market preference within the inflammatory rosacea therapy landscape. The company's strategy of leveraging its commercial infrastructure for high-margin products aligns with broader trends in specialty pharma to maximize efficiency and profitability.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks. However, the reported 21% year-over-year revenue growth and 146% quarter-over-quarter prescription growth for Emrosi are strong indicators of market acceptance and commercial success within the dermatology sector, especially for a recently launched product.
• The sequential improvement in gross margin to 67.4% suggests efficient product mix management, which is generally competitive for specialty pharmaceutical companies.
• The clinical superiority of Emrosi over Oracea (doxycycline) and placebo, as confirmed by Phase 3 data, sets a high standard for efficacy in rosacea treatment, potentially outperforming some existing therapies in the market.

Related Party Transactions

• The balance sheet shows "Due to related party" of $755 thousand as of September 30, 2025, and $528 thousand as of December 31, 2024.
• Journey Medical was founded by Fortress Biotech, Inc. (Nasdaq: FBIO), and Fortress controls a voting majority of Journey Medical's common stock.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved Adjusted EBITDA, and successful product commercialization (Emrosi). However, the "going concern" risk and Fortress Biotech's majority control are noted.
• Customers (Dermatologists & Patients): Emrosi's expanded payer access and validated clinical superiority offer a more accessible and effective treatment option for rosacea.
• Employees: Continued strong execution and commercial momentum suggest stability and potential growth opportunities.
• Creditors: The company's cash position increased, and net loss slightly narrowed, which could be viewed positively, but the "going concern" risk is a factor.

Next Steps

• Journey Medical management will conduct a conference call and audio webcast on November 12, 2025, at 4:30 p.m. ET to discuss financial results and provide a business update.
• Continued focus on the growth of Emrosi and leveraging the established dermatology commercial infrastructure to generate significant operating leverage.
• Ongoing efforts to gain recognition for Emrosi among dermatologists and patients to position it as a preferred treatment for inflammatory lesions of rosacea.

Key Dates

Recommendation

Journey Medical's Q3 2025 results show strong commercial execution, particularly with Emrosi driving significant revenue growth and improved Adjusted EBITDA. The expanded payer access and validated clinical superiority of Emrosi are strong positives. However, the company still reports a net loss, and the 'substantial doubt about our ability to continue as a going concern' risk, explicitly stated in the filing, warrants caution. While the operational momentum is encouraging, this significant going concern risk, coupled with the potential need for additional capital and reliance on a single key product for growth, suggests a 'hold' recommendation. Investors should monitor future filings for resolution of the going concern issue and continued progress towards sustained profitability.

Keywords

Dermatology, Pharmaceuticals, Emrosi, Rosacea Treatment, FDA-approved, Commercial-stage, Financial Results, Q3 2025, Nasdaq DERM, Biotech, Specialty Pharma